Skip to main content

Arcis Biotechnology: Steve Howell

Arcis Biotechnology, a nucleic acid sample prep provider, has appointed Steve Howell as non-executive chairman of the board. Howell will replace Paul Foulger, who was serving as chairman of the board on an interim basis. Howell is a professor of commercial innovation at King's College, London, a position he has held since 2015. He founded Innova Partnerships in 2006, and has previously served as director of business development at Alere and research director at Unipath.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.